Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

1
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (0)

Searched Name

CYP2C19 intermediate

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	Zhang Y, Zhao Y, Pang M, Wu Y, Zhuang K, Zhang H, Bhat A. High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. Acta Cardiol 2016;71:309-16. [PMID: 27594126 DOI: 10.2143/ac.71.3.3152091] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Abstract Collapse Key Words CYP2C19 intermediate high-dose clopidogrel poor metabolizers ticagrelor Collapse MESH Headings Acute Coronary Syndrome/genetics Acute Coronary Syndrome/mortality Acute Coronary Syndrome/therapy Adenosine/administration & dosage Adenosine/adverse effects Adenosine/analogs & derivatives Adenosine/pharmacokinetics Aged China/epidemiology Clopidogrel Cytochrome P-450 CYP2C19/genetics Dose-Response Relationship, Drug Drug Monitoring/methods Female Hemorrhage/chemically induced Hemorrhage/diagnosis Humans Kaplan-Meier Estimate Long Term Adverse Effects/diagnosis Long Term Adverse Effects/etiology Long Term Adverse Effects/mortality Male Middle Aged Percutaneous Coronary Intervention/methods Pharmacogenomic Testing/methods Purinergic P2Y Receptor Antagonists/administration & dosage Purinergic P2Y Receptor Antagonists/adverse effects Purinergic P2Y Receptor Antagonists/pharmacokinetics Ticagrelor Ticlopidine/administration & dosage Ticlopidine/adverse effects Ticlopidine/analogs & derivatives Ticlopidine/pharmacokinetics Treatment Outcome Collapse Grants Collapse Affiliation(s) Collapse

Number

Citation Analysis

Zhang Y, Zhao Y, Pang M, Wu Y, Zhuang K, Zhang H, Bhat A. High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. Acta Cardiol 2016;71:309-16. [PMID: 27594126 DOI: 10.2143/ac.71.3.3152091] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]